Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment

被引:3
|
作者
Ashaye, Ajibade [1 ]
Thomas, Caitlin [2 ]
Dalal, Mehul [1 ]
Kota, Vamsi [3 ]
Krucien, Nicolas [2 ]
Sae-Hau, Maria [4 ]
Weiss, Elisa [4 ]
Campbell, Scott [1 ]
Marsh, Kevin [2 ]
机构
[1] Takeda Dev Ctr Amer Inc, Lexington, MA 02421 USA
[2] Evidera, London W6 8BJ, England
[3] Augusta Univ, Sect Hematol & Oncol, Georgia Canc Ctr, Augusta, GA 30912 USA
[4] Leukemia & Lymphoma Soc, Rye Brook, NY 10573 USA
关键词
acute lymphoblastic leukemia; discrete choice experiment; hematologic neoplasms; patient preference; Philadelphia chromosome; shared decision making; tyrosine kinase inhibitor; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; TERM-FOLLOW-UP; PONATINIB; DECISIONS; IMATINIB; PHASE-2;
D O I
10.2217/fon-2022-0082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a discrete choice experiment, 201 patients chose between hypothetical treatment alternatives with varied levels of remission duration and overall survival (OS), and risks of major cardiovascular (CV) events and myelosuppression. Results: Although OS was the most important attribute to patients with Ph+ ALL, they were willing to tolerate a 2.9% increase in CV risk for 1 additional month of OS. Older patients (>59 years) and patients not in remission were less likely to tolerate increased CV risk. Conclusion: Preferences and risk tolerance varied between patients, highlighting the importance of shared decision making when selecting treatments for Ph+ ALL. Plain language summary Treatments differ in their potential benefits and side effects they may come with. Patients should be involved in deciding which treatments they receive. This is because patients may have different views than physicians on how the benefits and side effects of treatment would affect their quality of life. Additionally, patients may have different risk tolerances. This study shows how patients with a form of leukemia valued survival benefits and side effects of treatments, and the trade-offs that they were willing to make between these. On average, longer survival had most value to patients. They were willing to accept a higher risk of a major cardiovascular side effect (e.g., having a stroke) if the treatment would allow them to live longer. However, not all patients had the same opinion, and some groups of patients were less willing to accept risks to receive longer survival. By involving patients in treatment decisions, we can help ensure they receive treatments that match their personal preferences.
引用
收藏
页码:2075 / 2085
页数:11
相关论文
共 50 条
  • [21] Significance of micromegakaryocytes in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Kobayashi, S
    Maruta, A
    Yamamoto, T
    Fujisawa, S
    Fukawa, H
    Kanamori, H
    Matsuzaki, M
    Motomura, S
    Kodama, F
    Ishigatsubo, Y
    [J]. LEUKEMIA, 2000, 14 (07) : 1327 - 1329
  • [22] Current Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Fielding, Adele K.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 231 - 237
  • [23] Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults
    Saleh, Khalil
    Fernandez, Alexis
    Pasquier, Florence
    [J]. CANCERS, 2022, 14 (07)
  • [24] Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy
    Mainor, Candace B.
    Duffy, Alison P.
    Atkins, Kristin L.
    Kimball, Amy S.
    Baer, Maria R.
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (02) : 374 - 377
  • [25] Philadelphia chromosome-positive acute lymphoblastic leukemia and Down syndrome
    Tamaura, Moe
    Iwasaki, Fuminori
    Yokosuka, Tomoko
    Fukuda, Kunio
    Hamonoue, Satoshi
    Goto, Hiroaki
    [J]. PEDIATRICS INTERNATIONAL, 2016, 58 (08) : 794 - 797
  • [26] The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Sanford, David S.
    Kantarjian, Hagop
    O'Brien, Susan
    Jabbour, Elias
    Cortes, Jorge
    Ravandi, Farhad
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (04) : 365 - 373
  • [27] Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report
    Dai, Xingbin
    Tian, Fang
    Xu, Zuqiong
    Kong, Xiangtu
    Jiang, Pengjun
    Xia, Wen
    Zhu, Xuejun
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 742 - 748
  • [28] Significance of micromegakaryocytes in Philadelphia chromosome-positive acute lymphoblastic leukemia
    S Kobayashi
    A Maruta
    T Yamamoto
    S Fujisawa
    H Fukawa
    H Kanamori
    M Matsuzaki
    S Motomura
    F Kodama
    Y Ishigatsubo
    [J]. Leukemia, 2000, 14 : 1327 - 1329
  • [29] PHILADELPHIA CHROMOSOME-POSITIVE ACUTE-LEUKEMIA WITH LYMPHOBLASTIC CHARACTERISTICS
    KOBAYASHI, M
    TANAKA, Y
    HORINO, N
    TANAKA, T
    UEDA, K
    KOBAYASHI, Y
    USUI, T
    KAMADA, N
    [J]. HIROSHIMA JOURNAL OF MEDICAL SCIENCES, 1980, 29 (02) : 87 - 92
  • [30] Dasatinib - In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
    Keam, Susan J.
    [J]. BIODRUGS, 2008, 22 (01) : 59 - 69